Duromine weight loss pills — a brand of phentermine — are a prescription appetite suppressant used in some countries for short-term obesity management, but they are not licensed for use in the UK. The MHRA has not granted a marketing authorisation for phentermine-based products, meaning they cannot be legally prescribed through NHS or regulated UK private pathways. Despite this, Duromine frequently appears in online searches, and some websites illegally offer to supply it to UK addresses. This article explains how phentermine works, who qualifies for prescription weight management treatment in the UK, the safety risks involved, and which MHRA-licensed alternatives are available through regulated healthcare.
Summary: Duromine weight loss pills contain phentermine, an appetite suppressant that is not licensed for use in the UK and cannot be legally prescribed through NHS or regulated UK private prescribing pathways.
- Phentermine (Duromine) is a sympathomimetic amine that stimulates the central nervous system to suppress appetite by promoting noradrenaline release in hunger-regulating brain regions.
- The MHRA has not granted a UK marketing authorisation for Duromine or any phentermine-based product; purchasing it from online suppliers carries serious health and legal risks.
- Known safety concerns with phentermine include raised heart rate, elevated blood pressure, insomnia, anxiety, and a recognised potential for dependence; it is a controlled substance in several countries.
- MHRA-licensed UK alternatives for weight management include orlistat, semaglutide 2.4 mg (Wegovy), liraglutide 3 mg (Saxenda), and naltrexone–bupropion (Mysimba), all available via regulated prescribing.
- NICE guidance requires pharmacological weight management to be used alongside dietary, physical activity, and behavioural interventions, not as a standalone treatment.
- Suspected illegal supply of prescription medicines, including unlicensed weight loss products, should be reported to the MHRA's Enforcement and Intelligence Unit via gov.uk.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Is Duromine and How Does It Work?
Duromine is a brand name for phentermine, a prescription-only appetite suppressant used in some countries for short-term weight management in adults with obesity. Phentermine belongs to a class of medicines known as sympathomimetic amines, which work by stimulating the central nervous system in a manner similar to amphetamines. It promotes the release of noradrenaline in brain regions involved in regulating hunger and satiety, thereby reducing appetite and helping individuals consume fewer calories.
It is important to note that Duromine is not licensed for use in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has not granted a marketing authorisation for phentermine-based products such as Duromine, and phentermine is not routinely available through NHS or regulated UK private prescribing pathways. Any supply of an unlicensed medicine in the UK must follow strict MHRA-regulated named-patient or specials routes; such routes are not appropriate for weight management where licensed alternatives exist.
Phentermine does not hold a current UK marketing authorisation. It is worth noting that the withdrawals of weight loss medicines from the UK market in the 1990s primarily concerned fenfluramine and dexfenfluramine, which were associated with pulmonary arterial hypertension and valvular heart disease — particularly when used in combination. Phentermine's own regulatory history in the UK is distinct from these events, though it similarly lacks a current UK licence.
Duromine remains licensed in countries such as Australia, New Zealand, and South Africa, which is why it may appear in online searches. Patients who encounter websites offering to supply Duromine or phentermine to UK addresses should exercise extreme caution. Purchasing unlicensed medicines online carries significant health and legal risks: unregulated products may be counterfeit, contaminated, or supplied at incorrect doses, all of which pose serious patient safety concerns.
Who May Be Considered for Prescription Weight Loss Treatment?
In the UK, prescription weight loss treatments are considered within a structured clinical framework, guided by NICE guidance on obesity (CG189) and individual medicine-specific NICE Technology Appraisals. Pharmacological treatment is considered as an adjunct to lifestyle interventions — including dietary changes, increased physical activity, and behavioural support — rather than a standalone solution. Medicines are typically only considered when lifestyle measures alone have not produced sufficient weight loss.
Eligibility criteria vary depending on the specific medicine being considered. As a general principle:
-
Orlistat is typically considered for adults with a BMI of 28 kg/m² or above with associated risk factors, or 30 kg/m² or above without.
-
GLP-1 receptor agonists (such as semaglutide and liraglutide) have higher BMI thresholds and additional requirements set out in their respective NICE Technology Appraisals — including the presence of weight-related comorbidities and access through specialist weight management services (see the section on UK-approved alternatives below).
-
For individuals from South Asian, Chinese, or other high-risk ethnic backgrounds, NICE recognises that metabolic risk occurs at lower BMIs. For medicines with a standard BMI threshold, the applicable cut-off is generally 2.5 kg/m² lower for these groups (for example, a threshold of 32.5 kg/m² where the standard criterion is 35 kg/m²).
Prescription treatment is not appropriate for everyone. Contraindications vary by medicine but may include pregnancy, certain cardiovascular conditions, psychiatric disorders, or concurrent use of specific medications. A thorough medical assessment is essential before any pharmacological weight management treatment is initiated.
NICE guidance emphasises that treatment should form part of a comprehensive, multidisciplinary plan addressing the psychological, behavioural, and physiological aspects of obesity. Patients are encouraged to have realistic expectations and to understand that medicines support — but do not replace — sustainable lifestyle changes.
Possible Side Effects and Safety Considerations
Because phentermine (Duromine) does not hold a UK marketing authorisation, there is no MHRA-approved UK summary of product characteristics for it. Based on international clinical data from countries where it is authorised — such as Australia (TGA) and the United States (FDA) — phentermine is associated with a range of potential adverse effects.
Common side effects reported with phentermine include:
-
Increased heart rate (tachycardia) and elevated blood pressure
-
Insomnia and sleep disturbances
-
Dry mouth, constipation, and nausea
-
Nervousness, restlessness, or anxiety
-
Headaches and dizziness
More serious safety concerns include the risk of pulmonary arterial hypertension — a rare but potentially life-threatening condition affecting the blood vessels in the lungs — and valvular heart disease. It should be noted that the most robust evidence for these serious risks relates primarily to fenfluramine and dexfenfluramine, and to combination regimens involving phentermine with those agents; the evidence for phentermine monotherapy is more limited. Nevertheless, phentermine carries a recognised potential for dependence and misuse given its stimulant properties, and is classified as a controlled substance in some countries (for example, Schedule IV in the United States).
Patients should be particularly cautious about sourcing any weight loss medicine from unregulated online suppliers. The MHRA has repeatedly warned the public about the dangers of buying prescription medicines without a valid prescription from a registered UK prescriber. Counterfeit or substandard products may contain harmful ingredients, incorrect dosages, or no active ingredient at all.
If you experience chest pain, shortness of breath, palpitations, or severe mood changes whilst taking any weight loss product — whether prescribed or obtained elsewhere — seek urgent medical attention, contact your GP, or call NHS 111 immediately.
If you suspect you have experienced a side effect or product quality problem with any medicine, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.
UK-Approved Alternatives for Weight Management
For patients in the UK who are clinically eligible for pharmacological support with weight management, there are several MHRA-licensed options available through regulated healthcare pathways.
Orlistat (brand name Xenical, or available as a generic) is the most established prescription weight loss medicine in the UK. It works by inhibiting pancreatic lipase, an enzyme responsible for breaking down dietary fat in the gut, thereby reducing fat absorption by approximately 30%. It is available on prescription and, in a lower-dose formulation (Alli, 60 mg), can be purchased over the counter from pharmacies. Common side effects are gastrointestinal and include oily stools, flatulence, and faecal urgency, particularly if a high-fat diet is consumed.
GLP-1 receptor agonists represent a newer and increasingly prominent class of weight management medicines. These include:
-
Semaglutide 2.4 mg (Wegovy) — licensed by the MHRA and recommended by NICE (Technology Appraisal TA875) for weight management in adults. NICE criteria typically require a BMI of 35 kg/m² or above (or 32.5 kg/m² or above for some ethnic groups) with at least one weight-related comorbidity, and access through specialist NHS weight management services. Use is time-limited under NICE guidance. Note that Ozempic (semaglutide at a lower dose, licensed for type 2 diabetes) is not licensed for weight management in the UK and should not be used for this purpose outside its licensed indication.
-
Liraglutide 3 mg (Saxenda) — also licensed for weight management in the UK and recommended by NICE (Technology Appraisal TA664), administered as a daily subcutaneous injection. Similar specialist service and BMI requirements apply.
These medicines mimic the action of the naturally occurring hormone GLP-1, which regulates appetite and slows gastric emptying, leading to reduced food intake. They have demonstrated clinically meaningful weight loss in large-scale trials.
Naltrexone–bupropion (Mysimba) is another MHRA-licensed option for weight management in the UK. It acts on appetite-regulating pathways in the brain. Commissioning of Mysimba varies across NHS regions, and patients should discuss availability with their GP or specialist. As with other weight management medicines, it is used alongside dietary and lifestyle changes.
Patients should always access these treatments through a registered UK prescriber following a proper medical assessment, and should refer to the relevant MHRA-approved summary of product characteristics (SmPC) for full prescribing information.
Speaking to a GP About Weight Loss Support
If you are concerned about your weight and are considering medical support, the most appropriate and safest first step is to speak with your GP. A GP can assess your overall health, calculate your BMI, review any relevant medical history, and discuss whether pharmacological treatment is appropriate for your individual circumstances. They can also refer you to specialist NHS weight management services or a dietitian if needed.
It is understandable that many people feel frustrated with the pace of weight loss or find lifestyle changes difficult to sustain alone. However, it is important to approach weight management as a long-term health goal rather than seeking rapid results through unlicensed or unregulated products. Your GP can help you set realistic, evidence-based targets and provide ongoing support throughout the process.
When speaking to your GP, it may be helpful to:
-
Be honest about any previous weight loss attempts, including any supplements or medicines you may have tried
-
Mention any symptoms that concern you, such as fatigue, breathlessness, or joint pain related to your weight
-
Ask about referral options, including NHS Tier 3 or Tier 4 weight management services, which offer multidisciplinary support
-
Discuss your mental health, as emotional wellbeing is closely linked to eating behaviours and weight
If you believe a website or individual is illegally selling or advertising prescription medicines — including unlicensed weight loss products — you should report this to the MHRA's Enforcement and Intelligence Unit via the reporting form on the MHRA website (gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency). This is the correct channel for suspected illegal supply or advertising of medicines.
If you experience a suspected side effect or product quality problem with any medicine, report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Protecting yourself from unregulated products is an essential part of your overall health and safety.
Frequently Asked Questions
Can I get Duromine weight loss pills prescribed in the UK?
No — Duromine (phentermine) does not hold a UK marketing authorisation from the MHRA and cannot be legally prescribed through NHS or regulated UK private prescribing pathways. If you are looking for prescription weight loss support, a GP can discuss MHRA-licensed options such as orlistat or, where eligible, a GLP-1 receptor agonist like semaglutide (Wegovy).
Is it safe to buy Duromine online and have it shipped to the UK?
No — buying Duromine or any unlicensed prescription medicine from online suppliers and importing it to the UK carries serious health and legal risks. Unregulated products may be counterfeit, contaminated, or supplied at incorrect doses, and the MHRA has repeatedly warned the public against purchasing prescription medicines without a valid prescription from a registered UK prescriber.
What are the side effects of phentermine (Duromine)?
Common side effects of phentermine include increased heart rate, raised blood pressure, insomnia, dry mouth, constipation, nervousness, and headaches. More serious concerns include a potential risk of pulmonary arterial hypertension and a recognised capacity for dependence and misuse, given its stimulant properties.
What is the difference between Duromine and Wegovy for weight loss?
Duromine (phentermine) is a stimulant-based appetite suppressant that is not licensed in the UK, whereas Wegovy (semaglutide 2.4 mg) is an MHRA-licensed GLP-1 receptor agonist recommended by NICE for weight management in eligible adults. Wegovy works by mimicking the gut hormone GLP-1 to reduce appetite and slow gastric emptying, and it is available through specialist NHS weight management services for those who meet the clinical criteria.
Can I take weight loss pills alongside other medications I already use?
Whether any weight loss medicine is safe alongside your existing medications depends on the specific drugs involved and your medical history — this must be assessed by a registered prescriber before treatment begins. Some weight management medicines interact with antidepressants, antihypertensives, and other common drugs, so a thorough medicines review by your GP is essential.
How do I get a legitimate prescription for weight loss treatment in the UK?
The correct first step is to speak with your GP, who can assess your BMI, medical history, and eligibility for pharmacological treatment in line with NICE guidance. If appropriate, your GP can prescribe a licensed medicine such as orlistat, or refer you to a specialist NHS weight management service where GLP-1 receptor agonists such as Wegovy or Saxenda may be considered.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
